"空间组学分析好比是给每个细胞装上GPS定位，记录下空间位置信息和基因表达的特征。"林承棋介绍，这项研究前后历时6年，建构了多个覆盖 小鼠原肠运动后期至心脏等器官原基形成期的单细胞精度三维数字胚胎，累计解析超十万个细胞的基因表达信息。 东南大学研究团队建构的小鼠三维数字胚胎。（受访者供图） 新华社南京6月18日电（记者柯高阳）先天性心脏病是新生儿最常见的出生缺陷类型。我国科学家最新研究发现，哺乳动物胚胎发育早期存在一个 器官原基决定区，为先天性心脏病等出生缺陷防治与再生医学研究提供了关键理论基础。6月18日，国际学术期刊《细胞》在线发表了这一研究成 果。 研究发现，小鼠胚胎发育到7.75天时，胚内-胚外交界处出现一个独特的信号"洼地"——器官原基决定区（PDZ）。此时该区域紧邻的胚内、胚外 部分分别呈高浓度的信号抑制分子和激活性配体分子，但区域内呈现低信号活性"洼地"，表达多种受体信号基因，由此形成易于接收多胚层信号 调控输入、驱动心脏与前肠等器官原基协同发育的微环境。微环境信号被转化为基因选择性表达指令后，驱动心脏等器官原基形成。 哺乳动物早期胚胎的细胞团决定着心脏、肺、肝脏等器官的形成，其发育机制是生命科 ...

出品：新浪财经创投Plus 编辑整理：shu 基于公开数据不完全统计，2025年5月境内新增登记私募股权、创业投资基金管理人只有2家，较4月骤降83.3%，与2024年5月相比减少60%；新增备案私募 股权投资基金、创业投资基金合计339只，同比增长55.5%，环比下降18.7%。 备案红土种子基金专投前沿科技 5月投资事件数同、环比双增 结合中国证券投资基金业协会和天眼查公开披露的信息显示，深圳市创新投资集团有限公司（下文简称：深创投）是由深圳市政府出资并引导社会资本设立 的政府引导基金，目前管理资本规模超4700亿元。 2025年截至5月末，深创投仅登记备案了一只新基金——深圳市红土种子一号创业投资基金合伙企业（有限合伙），注册出资额共计3亿元，出资方LP除了 深创投，还有深圳市天使母基金和宝安区产业投资引导基金。公开报道显示，该基金整体存续期限为15年，锚定深圳"20+8"产业集群，重点布局人工智能、 智能终端、智能机器人等前沿领域，致力于支持具有自主知识产权、科技含量高、创新能力强的种子项目。 另外一只基金已注册的基金，为深圳市半导体与集成电路产业投资基金——深圳市赛米产业私募股权投资基金合伙企业（有 ...

Summary of Biotechni Conference Call Industry Overview - The life science tools industry is experiencing significant volatility due to macroeconomic factors and uncertainties, particularly in the U.S. and China [1][3] - The company has observed a recovery in the life science tools space, particularly in the pharmaceutical sector, which has shown double-digit growth across various geographies [3][4] Company Performance - The company reported double-digit growth in the pharmaceutical segment, which is widespread across its portfolio [4] - Academic revenue, which constitutes about 12% of total revenue, has been stable despite discussions of NIH budget cuts [5][6] - The worst-case scenario of a 40% cut in NIH funding would only result in a negative 1% impact on the company's projected growth rate over five years [6][7] Market Dynamics - Smaller biotech firms have been conservative in spending due to external market uncertainties, impacting their growth [9][10] - The pharmaceutical sector has seen a slight deceleration in growth rates from double digits to mid-single digits due to tariff discussions and pricing uncertainties [11][12] Academic Market Insights - Academic sales have remained stable despite concerns over funding cuts, attributed to the psychological impact on purchasing behavior [15][17] - Daily sales in the academic sector have shown stability over the past three months, indicating a return to normalcy [17] Instrumentation and Product Lines - The instrumentation segment, which accounts for about 20% of revenue, has seen growth driven by the biologics platform and specific products like the Maurice instrument [18][19] - The company is well-positioned in the bioprocessing market, with opportunities in biosimilars and other emerging markets [19][20] Tariff Impact and Mitigation Strategies - The company has low exposure to tariffs, with most of its reagents exempt from tariff increases [22][23] - Manufacturing strategies include moving production to Canada and stocking inventories in Europe and Asia to mitigate future tariff impacts [25][26] China Market Dynamics - China represents 88% of the company's revenues, and there are signs of a subtle shift towards optimism in customer demand [27][28] - The company is targeting the replacement of older instruments with newer technology, which is expected to drive growth [30][31] - Despite competition, the company maintains a strong position based on quality and consistency, which are prioritized by customers [34] Long-term Growth Outlook - The company remains bullish on long-term growth in China, driven by an aging population and ongoing scientific innovation [35][36] - The life science tools market is expected to grow significantly, with the company well-positioned to capitalize on these trends [37] Liquid Biopsy Segment - The liquid biopsy business is focused on scaling sustainably, with growth rates exceeding 20% [39] - The company is integrating exosome technology into its kit business, targeting multiple tests for disease monitoring [40][41] Spatial Market Position - The company is differentiating itself in the mid-plex spatial market by offering integrated solutions that combine molecular and antibody reagents [46][48] - The competitive landscape includes key players like Akoya and Molteni, but the company has a high win rate against these competitors [53] Margin Performance - The company achieved nearly 200 basis points of margin improvement year-over-year, although a contraction of approximately 150 basis points is expected in the near term due to tariffs and lower growth rates [54][55] - The long-term target is to achieve operating margins above 35%, supported by organic growth and effective cost management [55]

导读： Nature力荐的空间组学，质谱成像技术 (MSI) 凭借其多尺度可视化分析能力成关键驱动力，且在临床诊断和精准医疗中有广阔研究前景。5月13日再帕尔· 阿不力孜教授将出席ACCSI2025做前沿分享。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 在2 0 2 2年， Na tur e 将空间组学评为最值得期待的七项技术之一，彰显了其在生命科学领域的潜力。而在推动空间组学快速发展的背后，质谱 成像技术（Ma ss Sp e c tr ome tr y Ima g i n g，MSI）正发挥着不可替代的作用。 MSI技术具有显著的多尺度可视化分析能力，能够从整体动物、组织到组织微区乃至单细胞层面，实现分子的空间定位与定性分析。这一技术 不仅揭示了分子在生物体内的特异性分布，更为科学家提供了分子功能与空间位置之间的关键关联信息，从而深入解析生物化学过程以及分子 在生理与病理机制中的作用。与此同时，MSI技术推动空间多组学的发展，为揭示分子在生命活动及病变过程中的作用机制，为药物研发、疾 病发生发展机制研究和新型疾病标志物的发现等提供 ...